Latin America and the Caribbean vs Turkmenistan: Proportion of the target population who received the final dose of
Latin America and the Caribbean
69.0%
in 2024
Turkmenistan
99.0%
in 2024
Latin America and the Caribbean rank
4th
Turkmenistan rank
1st
Proportion of the target population who received the final dose of over time
- Latin America and the Caribbean
- Turkmenistan
How they compare
Turkmenistan currently reports 99.0% against 69.0% in Latin America and the Caribbean, a difference of 30.0%.
That makes Turkmenistan's figure about 1.4 times Latin America and the Caribbean's.
Across all 8 years both countries report, Turkmenistan has been ahead every year.
Latin America and the Caribbean ranks 4th and Turkmenistan ranks 1st of 35 groups.
Turkmenistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Latin America and the Caribbean | Turkmenistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 58.7% | 94.7% | 36.0% | Turkmenistan |
| 2020s | 49.4% | 98.6% | 49.2% | Turkmenistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received the final dose of, Latin America and the Caribbean or Turkmenistan?
- Turkmenistan, at 99.0% against 69.0% in Latin America and the Caribbean as of 2024.
- What is the difference in proportion of the target population who received the final dose of between Latin America and the Caribbean and Turkmenistan?
- 30.0%, with Turkmenistan ahead.
- How many years of comparable data are there for Latin America and the Caribbean and Turkmenistan?
- 8 years are reported by both, from 2017 to 2024.
- How do Latin America and the Caribbean and Turkmenistan rank globally for proportion of the target population who received the final dose of?
- Latin America and the Caribbean ranks 4th and Turkmenistan ranks 1st of 35 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received the final dose of human papillomavirus (HPV) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.